Letrozole IP CAS NO. 112809-51-5

Letrozole is a non-steroidal aromatase inhibitor used primarily in the treatment of hormone-dependent breast cancer in postmenopausal women. It works by selectively inhibiting the aromatase enzyme, thereby reducing estrogen synthesis in peripheral tissues and limiting the growth of estrogen-sensitive tumors. Letrozole is commonly prescribed as adjuvant therapy, extended adjuvant therapy, or for advanced and metastatic breast cancer, and is also used off-label for ovulation induction in infertility treatment. Owing to its high potency, oral bioavailability, and favorable clinical outcomes, letrozole is an important drug in endocrine therapy. Synonyms: Femara, CGS-20267, Letrozol, Letrozolum. About the Company GST Registration Date: 2022 Legal Status of Firm: Limited Company Number of Employees: Upto 10 People Annual Turnover: 1.5 - 5 Cr company-description: Incepted in the year 2022, "AVD Pharmaceuticals Private Limited" is distinguished API Intermidate Manufacture, Impurities, Fine chemical, Contract reserch, API Manufacture , Custom Synthises, Reserch and Development, And Pharamacitical Drug Product, and Importar-Exporter Trader, offering an enormous consignment and etc.